Exploring the potential of mixed-source brachytherapy for the treatment of cervical cancer using high-dose rate 192Ir and/or 50Â kV electronic sources

MSB is capable of providing target coverage to the cervix, uterus, and paracervical regions equivalent to that provided by HDR 192Ir, while significantly reducing the overall dose to the bladder, rectum, and bowel. This reduction is associated with small regions of increased dose in a significant proportion of patients.